To study the mechanisms of hepatocyte injury, we examined serum interleukin-6 (IL-6) level in acute hepatitis patients. Based on their clinical features, these patients were divided into three groups, acute hepatitis (AH), severe acute hepatitis, and fulminant hepatic failure (FHF). The present study demonstrated that, in association with their clinical status, their serum IL-6 levels were gradually increased (16.5±14.5 pg/ml in AH, 26.3±19.0 pg/ml in severe AH, and 470.2±261.4 pg/ml in FHF; control level, 5.2±0.6 pg/ml). Furthermore, we found that a significant correlation between serum IL-6 level and prothrombin time existed in these patients and that the elevated serum IL-6 returned to a normal range after recovery from their hepatocyte injury. Thus, our study demonstrates that the serum IL-6 level is a possible marker for identifying the clinical status in acute hepatitis and that this cytokine may have some roles in hepatocyte injury.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Büschenfelde K-HMZ, Manns M: Mechanisms of autoimmune liver disease. Semin Liver Dis 4:26–35, 1984
Van Hattum J, Van Oudenaren A, Schalm SW, Visser JWM, Benner R: T-lymphocyte subpopulation in patients with various courses after hepatitis B virus infection. Scand J Gastroenterol 19:497–501, 1984
Hodgson HJ, Wands JR, Isselbacher KJ: Alteration in suppressor cell activity in active chronic hepatitis. Proc Natl Acad Sci USA 75:1549–1551, 1978
Thestrup-Peterson K, Ladefoged K, Andresen L: Lymphocyte transformation test with liver specific protein and phytohemagglutinin in patients with liver disease. Clin Exp Immunol 24:1–7, 1976
Wands JR, Perrotto JL, Alpert E, Isselbacher KJ: Cellmediated immunity in acute and chronic hepatitis. J Clin Invest 55:921–929, 1975
Thomson AD, Cochrane MA, McFarlane IG, Eddleston AL, Williams R: Lymphocyte cytotoxicity to isolated hepatocyte in chronic active hepatitis. Nature 252:721–722, 1974
Thomas HC, Brown D, LaBrooy J, Epstein O: T cell subsets in autoimmune and HBV-induced chronic liver disease. A review of the abnormalities and the effects of treatment. Liver 2:266–269, 1982
Carella G, Chatenoud L, Degos F, Bach MA: Regulatory T cell subset imbalance in chronic active hepatitis. J Clin Immunol 2:93–100, 1982
Hasegawa K, Yamauchi K, Furukawa T, Obata H: Dual color fluorescence analysis of peripheral T cell subsets in hepatitis B virus-induced liver disease. Hepatology 8:1134–1137, 1988
Kishimoto T: Factors affecting B cell growth and differentiation. Annu Rev Immunol 3:133–157, 1985
Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M,et al.: Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228–231, 1987
Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K,et al.: Excessive production of interleukin-6/ B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18:1797–1801, 1988
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwata K, Asaoku H,et al.: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85, 1988
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T,et al.: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in castleman's disease. Blood 74:1360–1367, 1989
Muto Y, Nouri-Aria KT, Meager A, Alexander GJM, Eddleston AL, Williams R: Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 9:72–74, 1988
Trey C, Davidson C: The management of fulminant hepatic failure. Prog Liver Dis 3:282–298, 1970
Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, Yamamura Y: T cell-replacing factor (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127:412–416, 1981
Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S,et al.: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73–76, 1986
Bot FJ, Eijk L, Broeders L, Aarden LA, Löwenberg B: Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. Blood 73:435–437, 1989
Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kaziro Y: Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin-6. Mol Cell Biol 8:3546–3549, 1988
Van Damme J, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billiau A,et al.: Identification of the human 26-KD protein. Interferon β2 (IFN-β2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 165:914–919, 1987
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H: Interferon β2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255, 1987
Defilippi P, Poupart P, Tavernier J, Fiers W, Content J: Induction and regulation of mRNA encoding 26-KDa protein in human cell lines treated with recombinant human tumor necrosis factor. Proc Natl Acad Sci USA 84:4557–4561, 1987
About this article
Cite this article
Sun, Y., Tokushige, K., Isono, E. et al. Elevated serum interleukin-6 levels in patients with acute hepatitis. J Clin Immunol 12, 197–200 (1992). https://doi.org/10.1007/BF00918089
- acute hepatitis
- hepatocyte injury
- fulminant hepatic failure
- prothrombin time